Why You Won't See a Wegovy Advert on UK Television

You scroll past something that looks like a Wegovy advert, here is what it probably was

Picture this: you have been researching weight-loss options, and an ad slides into your feed. It shows a branded pen, a before-and-after implication, and a link to buy. It looks professional. It may even use Wegovy's colour palette. But if it is asking you to purchase a prescription medicine without directing you first to a clinical assessment, it is not a compliant advertisement, it is an offer to sell you a prescription drug outside the legal framework that exists to keep you safe.

The MHRA has been clear in its public guidance that GLP-1 receptor agonist medicines, including semaglutide, are not suitable for cosmetic weight loss or rapid results, and that promotional content framing them that way misrepresents what they are. Real information about Wegovy and how it works looks quite different: it talks about clinical assessment, BMI thresholds, and the prescriber's role. It does not offer a checkout button.

There is also a practical safety dimension here. The MHRA raided an illicit manufacturing site producing counterfeit tirzepatide pens in 2025, and fake semaglutide products have caused hospitalisations. Advertising-style content from unverified sellers is one of the main routes through which counterfeit medicines reach people. If the post is selling urgency rather than clinical care, that is a signal worth acting on.

What UK law actually says about advertising prescription medicines

The Human Medicines Regulations 2012 are unambiguous. Regulation 7 and Part 14 together prohibit the promotion of prescription-only medicines to the public. This applies equally to pharmaceutical manufacturers, pharmacies, clinicians, and influencers. A drug company cannot legally run a campaign telling the British public to ask their doctor for Wegovy by name, the kind of direct-to-consumer advertising common in the United States has never been permitted here.

What is permitted is disease-awareness content: information about obesity as a health condition, about treatment pathways, about how to access clinical assessment. The line sits between educating someone that a treatment category exists and promoting a specific prescription product as desirable. Legitimate services providing weight-loss treatment information stay firmly on the education side of that line.

The MHRA monitors this actively. Complaints about unlawful promotion of prescription medicines can be reported to the agency, and the Yellow Card scheme also accepts reports about suspect sellers, something worth knowing if you come across content that seems designed to bypass clinical safeguards. You can read the MHRA's own public guidance on GLP-1 medicines on GOV.UK for a plain account of what these medicines are and are not for.

What a legitimate source of Wegovy information looks like

Here is where a common misconception quietly deserves to be set aside. A lot of people assume that if a service looks polished and the website seems professional, the advertising rules must not apply to it, or that it has some kind of exemption. They do not. A GPhC-registered pharmacy providing information about semaglutide is bound by exactly the same legal framework as a large manufacturer. The difference between compliant and non-compliant content is not about design quality, it is about whether clinical assessment is genuinely central to the process, or whether it is theatre.

Compliant information will: explain that Wegovy is a prescription medicine requiring clinical review; describe the licensed eligibility criteria (BMI thresholds, weight-related conditions) without guaranteeing anyone approval; reference the prescriber's role; and point to authoritative sources. The NHS medicines page for semaglutide is a good benchmark, clear, factual, no promotional angle. The side-effect profile of semaglutide is also covered properly in patient-facing NHS content, including the gastrointestinal effects most people notice early in treatment.

If you want to understand how the rules around semaglutide advertising work and what compliant promotional content must include, the regulatory framework answers those questions clearly, and our guide to what a semaglutide advertisement can and cannot legally say walks through specific examples of where promotional content crosses the line. Cost is a separate but related concern: how Wegovy is priced privately in the UK tells you what a legitimate prescription route involves financially, which is a useful counterweight to the suspiciously cheap listings you sometimes see in social-media content.

How nume's prescribers approach this

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, not an automated filter. They assess whether semaglutide is clinically appropriate for you, look at your full health picture, and make a recommendation accordingly. There are no guarantees of approval and no promotional incentives tied to the outcome. That is what clinical assessment is supposed to look like.

The service does not run discount codes, flash sales, or urgency-led offers, not because of a policy quirk, but because those mechanics are incompatible with what it means to supply a prescription medicine responsibly. If you would like to find out whether Wegovy might be suitable for you, the starting point is a conversation with our clinical team, not an advert. You can read more about how to insert Wegovy correctly once it has been prescribed to you so you are prepared from the outset, or check the FAQs for common questions about the process. When you are ready, start your free consultation and a prescriber will review your answers the same day.